PureTech Health plc
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert William Henry Lyne
- Full Time Employees
- 56
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 6 Tide Street Boston MA United States of America 02210
- IPO Date
- Nov 16, 2020
- CIK
- 0001782999
- Website
- puretechhealth.com
- Similar Companies
- Business
- PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) is a clinical-stage biotherapeutics company that discovers, develops and commercializes differentiated medicines for devastating diseases through its hub-and-spoke model, which includes wholly-owned programs and Founded Entities advancing therapeutics in oncology, immunology, neurology, lymphatic and gastrointestinal disorders; core wholly-owned candidates comprise deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis and other fibrotic lung diseases, LYT-200 (an anti-galectin-9 monoclonal antibody) for hematological malignancies including acute myeloid leukemia and high-risk myelodysplastic syndromes as well as solid tumors such as head and neck cancers, LYT-300 (oral allopregnanolone) for anxiety disorders and postpartum depression, and Glyph platform-derived neuropsychiatric therapies including GlyphAgo (SPT-320) for generalized anxiety disorder and major depressive disorder, Glyph2BLSD (SPT-348) for headache disorders and treatment-resistant depression; Founded Entities such as Gallop Oncology (wholly-owned, advancing LYT-200), Seaport Therapeutics (advancing Glyph-derived CNS candidates), Celea Therapeutics (advancing LYT-100), Vedanta Biosciences (live biotherapeutic products for immuno-oncology, inflammatory bowel disease and food allergies), and others including legacy successes like Karuna Therapeutics (whose KarXT/Cobenfy received FDA approval for schizophrenia and was acquired by Bristol Myers Squibb for $14 billion in 2023, generating PureTech approximately $1.1 billion from an $18.5 million investment including a Royalty Pharma royalty deal). Founded in 2005 and headquartered in Boston, Massachusetts, with a registered office in London, United Kingdom, the company operates primarily in the United States and targets patients with high unmet needs in major therapeutic areas through clinical-stage programs, three of which have secured FDA approvals via Founded Entities. Recent developments include the launch of Celea Therapeutics in August 2025 to advance Phase 3-ready LYT-100, spin-outs of Seaport Therapeutics (raising over $325 million in 2024 oversubscribed financings) and Gallop Oncology to focus on oncology assets, topline data from LYT-200 trials demonstrating clinical activity in AML and disease control in head and neck cancer, Phase 2b progress for LYT-100 with presentation planned for May 2025, strategic discussions with Nordic Capital regarding a potential acquisition, ongoing financing efforts for Celea and Gallop to extend cash runway into 2028 with $320 million in reserves, and equity monetizations including from Karuna's Bristol Myers Squibb acquisition.
PureTech Health: Results of Annual General Meeting
PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
PureTech Health plc (PRTC) Q4 2025 Earnings Call Transcript
PureTech Announces Annual Results for Year Ended December 31, 2025
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)
PureTech Health: Notice of Results
PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
Short Interest in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Rises By 140.8%
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
PureTech to Present at the Leerink Partners Global Healthcare Conference
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
PureTech Health plc (PRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference
PureTech Appoints Robert Lyne as Chief Executive Officer
Puretech gains after FDA meeting post-Phase II trial
Cavendish sees Poolbeg’s POLB 001 gaining strategic importance as CRS research expands